Cambridge Innovation Capital has returned for a series C round for University of Cambridge-linked Gyroscope Therapeutics, which also welcomed back Syncona.

The solid tumour therapy developer secured $21.9m from investors including Dai-ichi Life, Binex, Bigen and Shibuya Kogyo.

Helsinn and Johnson & Johnson returned to add $21m in extra funding to the $44m series B round the surgical marker developer closed in 2018.

The University of Utah spinout is looking to float on the Nasdaq Global Select Market and has filed with a $100m placeholder amount.

Evidation, co-founded by Stanford University and GE Ventures, has picked up series E funding at a $1bn valuation.

The gene therapy developer focused on cardiovascular and central nervous system diseases will merge with Chardan Healthcare Acquisition 2 Corp to list on NYSE.

Stuart Therapeutics has collected equity financing from investors including Wisconsin Alumni Research Foundation to fund phase 2 trials for a drug aimed at dry eye disease.

The WuXi AppTec-backed infectious disease therapeutics developer has closed a series C round featuring various investment managers and Singapore's sovereign wealth fund.

New and existing investors provided crossover financing for the synthetic biology technology developer, which already counts Merck & Co, AGC Asahi Glass and JSR Life Sciences as investors.

Bayer could exit the drug discovery technology developer should it complete an initial public offering on the Nasdaq Global Select Market.